KURA · Kura Oncology Inc. Common Stock
View on chartInsiders & Stakes
| Troy Edward Wilson Director | ▲ Buy | Option Exercise | 435,456 Shares held | 3/23/2026 | View profile |
| Teresa Brophy Bair Chief Legal Officer | ▼ Sell | Open Market | 226,931 Shares held | 5/18/2026 | View profile |
| Mollie Leoni Chief Medical Officer | ▼ Sell | Open Market | 182,345 Shares held | 6/18/2026 | View profile |
| Brian T. Powl Chief Commercial Officer | ▼ Sell | Open Market | 173,614 Shares held | 5/21/2026 | View profile |
| Kathleen Ford Chief Operating Officer | ▼ Sell | Open Market | 153,560 Shares held | 5/19/2026 | View profile |
| Thomas James Doyle SVP, Finance & Accounting | ▼ Sell | Open Market | 145,167 Shares held | 1/27/2026 | View profile |
| Francis Burrows Chief Scientific Officer | ▼ Sell | Open Market | 32,424 Shares held | 1/27/2026 | View profile |
| Faheem Hasnain President & CEO | ▼ Sell | Open Market | 23,983 Shares held | 12/9/2025 | View profile |
| Thomas Malley Director | ▲ Buy | Option Exercise | 10,000 Shares held | 3/18/2026 | View profile |
Transaction History
| Mollie Leoni | ▼ Sell | Open Market | 84,929 | $834K | 6/18/2026 |
| Brian T. Powl | ▼ Sell | Open Market | 10,000 | $110K | 5/21/2026 |
| Brian T. Powl | ▼ Sell | Open Market | 339 | $3K | 5/19/2026 |
| Kathleen Ford | ▼ Sell | Open Market | 2,257 | $20K | 5/19/2026 |
| Teresa Brophy Bair | ▼ Sell | Open Market | 2,256 | $21K | 5/18/2026 |
| Troy Edward Wilson | ▲ Buy | Option Exercise | 6,103 | $38K | 3/23/2026 |
| Thomas Malley | ▲ Buy | Option Exercise | 10,000 | $31K | 3/18/2026 |
| Brian T. Powl | ▼ Sell | Open Market | 1,572 | $13K | 1/27/2026 |
| Kathleen Ford | ▼ Sell | Open Market | 1,813 | $15K | 1/27/2026 |
| Mollie Leoni | ▼ Sell | Open Market | 3,655 | $31K | 1/27/2026 |
| Mollie Leoni | ▼ Sell | Open Market | 2,233 | $19K | 1/27/2026 |
| Mollie Leoni | ▼ Sell | Open Market | 951 | $8K | 1/27/2026 |
| Thomas James Doyle | ▼ Sell | Open Market | 695 | $6K | 1/27/2026 |
| Thomas James Doyle | ▼ Sell | Open Market | 2,226 | $19K | 1/27/2026 |
| Thomas James Doyle | ▼ Sell | Open Market | 881 | $7K | 1/27/2026 |
| Francis Burrows | ▼ Sell | Open Market | 1,311 | $11K | 1/27/2026 |
| Teresa Brophy Bair | ▼ Sell | Open Market | 4,096 | $35K | 1/27/2026 |
| Teresa Brophy Bair | ▼ Sell | Open Market | 2,335 | $20K | 1/27/2026 |
| Teresa Brophy Bair | ▼ Sell | Open Market | 4,777 | $40K | 1/27/2026 |
| Brian T. Powl | ▼ Sell | Open Market | 4,842 | $41K | 1/27/2026 |
| Mollie Leoni | ▼ Sell | Open Market | 1,341 | $11K | 1/27/2026 |
| Thomas James Doyle | ▼ Sell | Open Market | 2,226 | $19K | 1/27/2026 |
| Thomas James Doyle | ▼ Sell | Open Market | 1,114 | $9K | 1/27/2026 |
| Mollie Leoni | ▲ Buy | Grant | 50,000 | $0 | 1/2/2026 |
| Thomas James Doyle | ▲ Buy | Grant | 21,250 | $0 | 1/2/2026 |
| Kathleen Ford | ▲ Buy | Grant | 50,000 | $0 | 1/2/2026 |
| Brian T. Powl | ▲ Buy | Grant | 50,000 | $0 | 1/2/2026 |
| Teresa Brophy Bair | ▲ Buy | Grant | 50,000 | $0 | 1/2/2026 |
| Francis Burrows | ▲ Buy | Option Exercise | 35,000 | $168K | 12/18/2025 |
| Francis Burrows | ▼ Sell | Open Market | 23,726 | $232K | 12/18/2025 |
| Faheem Hasnain | ▲ Buy | Option Exercise | 10,000 | $31K | 12/9/2025 |
| Faheem Hasnain | ▼ Sell | Open Market | 10,000 | $110K | 12/9/2025 |
| Brian T. Powl | ▼ Sell | Open Market | 8,887 | $99K | 11/14/2025 |
| Kathleen Ford | ▼ Sell | Open Market | 6,902 | $77K | 11/14/2025 |
| Teresa Brophy Bair | ▼ Sell | Open Market | 8,804 | $98K | 11/14/2025 |
| Mollie Leoni | ▼ Sell | Open Market | 15,485 | $173K | 11/14/2025 |
| Thomas James Doyle | ▼ Sell | Open Market | 4,539 | $51K | 11/14/2025 |
| Mollie Leoni | ▲ Buy | Grant | 82,500 | $0 | 11/13/2025 |
| Thomas James Doyle | ▲ Buy | Grant | 24,967 | $0 | 11/13/2025 |
| Troy Edward Wilson | ▲ Buy | Grant | 182,500 | $0 | 11/13/2025 |
| Brian T. Powl | ▲ Buy | Grant | 48,900 | $0 | 11/13/2025 |
| Kathleen Ford | ▲ Buy | Grant | 48,900 | $0 | 11/13/2025 |
| Teresa Brophy Bair | ▲ Buy | Grant | 48,900 | $0 | 11/13/2025 |
| Brian T. Powl | ▼ Sell | Open Market | 8,891 | $80K | 9/29/2025 |
| Teresa Brophy Bair | ▼ Sell | Open Market | 8,805 | $79K | 9/29/2025 |
| Kathleen Ford | ▼ Sell | Open Market | 6,892 | $62K | 9/29/2025 |
| Mollie Leoni | ▼ Sell | Open Market | 12,314 | $110K | 9/29/2025 |
| Troy Edward Wilson | ▼ Sell | Open Market | 36,615 | $327K | 9/29/2025 |
| Brian T. Powl | ▲ Buy | Grant | 48,900 | $0 | 9/27/2025 |
| Teresa Brophy Bair | ▲ Buy | Grant | 48,900 | $0 | 9/27/2025 |
| Kathleen Ford | ▲ Buy | Grant | 48,900 | $0 | 9/27/2025 |
| Mollie Leoni | ▲ Buy | Grant | 82,500 | $0 | 9/27/2025 |
| Troy Edward Wilson | ▲ Buy | Grant | 182,500 | $0 | 9/27/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Kura Oncology Secures $50M for Diabetes Menin Inhibitor Project
Kura Oncology announced a $50 million partnership to develop an oral menin inhibitor for diabetes. The company will work with Caspian Therapeutics on KO‑7246, sharing data and a joint development plan. The move expands Kura’s focus beyond oncology into chronic metabolic diseases. The collaboration signals confidence in the drug’s potential for diabetes treatment.
Kura Oncology Secures $50M for Diabetes Menin Inhibitor Project. Kura Oncology announced a $50 million partnership to develop an oral menin inhibitor for diabetes. The company will work with Caspian Therapeutics on KO‑7246, sharing data and a joint development plan. The move expands Kura’s focus beyond oncology into chronic metabolic diseases. The collaboration signals confidence in the drug’s potential for diabetes treatment.